Skip to main content

Market Overview

The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Here's a roundup of top developments in the biotech space over the last 24 hours.

No biotech stock hit 52-week high in Wednesday's session.

Down In The Dumps

(Biotech stocks hitting 52-week lows on Dec. 12)

  • Achieve Life Sciences Inc (NASDAQ: ACHV)
  • Aileron Therapeutics Inc (NASDAQ: ALRN)
  • Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)
  • Bioanalytical Systems, Inc. (NASDAQ: BASI)
  • Biomerica, Inc. (NASDAQ: BMRA)
  • Bio-Path Holdings Inc (NASDAQ: BPTH)
  • Epizyme Inc (NASDAQ: EPZM)
  • Evogene Ltd (NASDAQ: EVGN)
  • IntelliPharmaCeutics Intl Inc(NASDAQ: IPCI)
  • Melinta Therapeutics Inc (NASDAQ: MLNT)
  • Nemaura Medical Inc (NASDAQ: NMRD)(announced acceptance of SugarBEAT Clinical Performance Data Abstract presentation at Advanced Technologies and Treatments for Diabetes Conference in Feb. 2019)
  • Neurotrope Inc (NASDAQ: NTRP)
  • Oncomed Pharmaceuticals Inc (NASDAQ: OMED)
  • Ophthotech Corp (NASDAQ: OPHT)
  • OptiNose Inc (NASDAQ: OPTN)(announced that Avanir Pharma has terminated the license agreement it had with OptiNose for developing Onzetra XSAIL in the U.S., Canada and Mexico)
  • Ovid Therapeutics Inc (NASDAQ: OVID)
  • Pluristem Therapeutics Inc. (NASDAQ: PSTI)
  • Sierra Oncology Inc (NASDAQ: SRRA)
  • Synergy Pharmaceuticals Inc (NASDAQ: SGYP)(filed for Chapter 11 bankruptcy protection, with Bausch Health Companies Inc (NYSE: BHC) now emerging as the stalking horse bidder in a court approved auction and sales process)
  • TherapeuticsMD Inc (NASDAQ: TXMD)
  • Trillium Therapeutics Inc (NASDAQ: TRIL)
  • Unum Therapeutics Inc (NASDAQ: UMRX)
  • Urovant Sciences Ltd (NASDAQ: UROV)
  • Vaccinex Inc (NASDAQ: VCNX)
  • Wright Medical Group NV (NASDAQ: WMGI)

See Also: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Stocks In Focus

VIVUS Extends Supply Agreement With Sanofi

VIVUS, Inc. (NASDAQ: VVUS) announced an amended supply deal with Novartis AG (NYSE: NVS)'s Sanofi Chimie, which provides for the latter manufacturing and supplying API for Vivus' avanafil, on an exclusive basis, beginning Jan. 1, 2019. The amendment also provides for adjustment of the yearly minimum quantities of API that Vivus must purchase, as well as pricing and payment terms, beginning Jan. 1.

The supply agreement has been extended until Dec. 31, 2023. The original deal was struck in July 2013.

The stock rallied 8.42 percent to $3.07 in after-hours trading.

Applied Genetic's Gene Therapy Not Effective, Snaps Ties With Biogen

Applied Genetic Technologies Corp (NASDAQ: AGTC) said interim six-month data from the Phase 1/2 trial of rAAV2tYF-CB-hRS1, an investigational AAV-based gene therapy, delivered via intravitreal injection for X-linked retinoschisis clinical study, showed the gene delivery platform did not demonstrate signs of clinical activity. The platform, however, was found safe and tolerable.

The company also said it has terminated its collaboration agreement with Biogen Inc (NASDAQ: BIIB) effective March 8, 2018, and consequently regained full rights to the X-linked retinoschisis and X-linked retinitis pigmentosa programs and the three other partnered discovery programs.

Despite the snapping of ties with Biogen, Applied Genetic Tech said its previous guidance is unchanged.

The stock slumped 38.72 percent to $4.02 in after-hours trading.

EC Okays Novartis' Injectable Asthmatic Allergy Biologic Drug

Novartis said the European Commission has approved its Xolair prefilled syringe for self-administration by patients with severe allergic asthma and chronic spontaneous urticaria.

Xolair is administered via injection every two or four weeks.

Zynerba's Cannabinoid Drug Produces Sustained Improvement In Fragile X Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported new 12-month open label clinical trial data that explains the long term impact of ZYN002, a transdermal cannabinoid gel, on emotional and behavioral symptoms of Fragile X Syndrome, which showed sustained improvement over a period of 12 months.

After 12 months of treatment with ZYN002, patients experienced a 77 percent improvement in aberrant behaviors associated with social avoidance compared to the baseline.

The data is to be presented in the form of a poster at the 57th Annual Meeting of the American College of Neuropsychopharmacology held in the Diplomat Beach Resort in Hollywood, Florida.

Zynerba shares rallied 9.11 percent to $5.15 in after-hours trading.

Zoetis to Buy Back $2B Shares

Zoetis Inc (NYSE: ZTS) said its board has authorized a $2 billion multi-year share repurchase program as part of its long-tern capital allocation plans. The previous $1.5 billion buyback program announced Dec. 2016 is expected to be completed in the first-half of 2019.

The company's board also approve a 30 percent increase its quarterly dividend to 16.4 cents per share.


Tocagen Inc (NASDAQ: TOCA) said it has priced its underwritten public offering of 3 million shares at $10 per share, which would generate gross proceeds of about $30 million. The offering is expected to close on or about Dec. 17.

The stock pulled back 5.08 percent to $10.66 in after-hours trading.

VBI Vaccines Inc (NASDAQ: VBIV) announced the commencement of an underwritten public offering of its common shares, although it did not specify the size of the offering. The company intends to use the net proceeds, primarily to fund its clinical programs.

The stock plunged 10.78 percent to $1.49 in after-hours trading.

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) said it has priced its previously announced public offering of 12 million shares at $3.75 per share, with the total size of the offering at $45 million.

The stock slipped 2.85 percent to $4.09 in after-hours trading.

On The Radar


Pure Bioscience, Inc. (OTC: PURE) (after the market close)

Clinical Trial Results

Imv Inc (NASDAQ: IMV) will host a webcast and conference call to discuss its ESMO Immuno-oncology conference poster presentation of updated Phase 1b/2 data for its ovarian cancer pipeline candidate DPX-Survivac, which is low dose cyclophosphamide, along with epacadostat. The poster presentation is scheduled for Dec. 14-15.


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Offerings Contracts Top Stories Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at